Inovio’s upside hinges on INO-3107 for HPV-6/11 RRP with FDA PDUFA Oct 2026, regulatory risk, tight cash, and cheap EV. Check ...

Inovio has changed its chief commercial officer ahead of the planned launch of its first DNA medicine, putting Merck veteran Steven Egge in charge of leading the strategy and operations. The DNA ...

Inovio Pharmaceuticals (NASDAQ:INO) is preparing to release its quarterly earnings on Thursday, 2024-11-14. Here's a brief overview of what investors should keep in mind before the announcement.

Inovio Pharmaceuticals Inc. (NASDAQ: INO) stock fell Monday after the U.S. Food and Drug Administration accepted the company’s Biologics License Application (BLA) for INO-3107 but raised concerns tied ...

PLYMOUTH MEETING, Pa., Dec. 19, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from ...

(Reuters) - Inovio Pharmaceuticals Inc will discontinue a late-stage study of its COVID-19 vaccine, the company said on Tuesday, and appointed its operating chief as the new chief executive, sending ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min After failing to develop a Covid ...

This was the stock's third consecutive day of losses.

Shares of Inovio Pharmaceuticals pulled back by 5.3% during Wednesday’s session. The decline may be attributed to profit-taking, as investors assess renewed focus on respiratory illnesses. See the ...

The stock's fall snapped a two-day winning streak.